EDIT

Company Overview — What Does Editas Medicine, Inc. Do?

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine, Inc. (EDIT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gilmore O’Neill and employs approximately 230 people, headquartered in CAMBRIDGE, Massachusetts. With a market capitalization of $255M, EDIT is one of the notable companies in the Healthcare sector.

Editas Medicine, Inc. (EDIT) Stock Rating — Reduce (April 2026)

As of April 2026, Editas Medicine, Inc. receives a Reduce rating with a composite score of 26.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.EDIT ranks #3,199 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Editas Medicine, Inc. ranks #482 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

EDIT Stock Price and 52-Week Range

Editas Medicine, Inc. (EDIT) currently trades at $2.86. The stock lost $0.03 (0.9%) in the most recent trading session. The 52-week high for EDIT is $4.54, which means the stock is currently trading -36.9% from its annual peak. The 52-week low is $0.91, putting the stock 214.7% above its annual trough. Recent trading volume was 1.6M shares, reflecting moderate market activity.

Is EDIT Overvalued or Undervalued? — Valuation Analysis

Editas Medicine, Inc. (EDIT) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.83x, versus the sector average of 2.75x. The price-to-sales ratio is 16.93x, compared to 1.66x for the average Healthcare stock.

At current multiples, Editas Medicine, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Editas Medicine, Inc. Profitability — ROE, Margins, and Quality Score

Editas Medicine, Inc. (EDIT) earns a quality factor score of 13/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -793.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -116.1% versus the sector average of -33.1%.

On a margin basis, Editas Medicine, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -27762.6% (sector: -66.1%). Net profit margin stands at -26331.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1370.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

EDIT Debt, Balance Sheet, and Financial Health

Editas Medicine, Inc. has a debt-to-equity ratio of 584.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $59M. Cash and equivalents stand at $166M.

EDIT has a beta of 2.05, meaning it is more volatile than the broader market — a $10,000 investment in EDIT would be expected to move 104.8% more than the S&P 500 on any given day. The stability factor score for Editas Medicine, Inc. is 16/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Editas Medicine, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Editas Medicine, Inc. reported revenue of $16M and earnings per share (EPS) of $-1.80. Net income for the quarter was $-217M. Gross margin was 100.0%. Operating income came in at $-218M.

In FY 2025, Editas Medicine, Inc. reported revenue of $41M and earnings per share (EPS) of $-1.80. Net income for the quarter was $-160M. Revenue grew 25.4% year-over-year compared to FY 2024. Operating income came in at $-160M.

In Q3 2025, Editas Medicine, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-25M. Revenue grew 12265.6% year-over-year compared to Q3 2024. Operating income came in at $-25M.

In Q2 2025, Editas Medicine, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.63. Net income for the quarter was $-53M. Revenue grew 597.5% year-over-year compared to Q2 2024. Operating income came in at $-52M.

Over the past 8 quarters, Editas Medicine, Inc. has demonstrated a growth trajectory, with revenue expanding from $513,000 to $16M. Investors analyzing EDIT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

EDIT Dividend Yield and Income Analysis

Editas Medicine, Inc. (EDIT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

EDIT Momentum and Technical Analysis Profile

Editas Medicine, Inc. (EDIT) has a momentum factor score of 54/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.

EDIT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Editas Medicine, Inc. (EDIT) ranks #482 out of 838 stocks based on the Blank Capital composite score. This places EDIT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing EDIT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full EDIT vs S&P 500 (SPY) comparison to assess how Editas Medicine, Inc. stacks up against the broader market across all factor dimensions.

EDIT Next Earnings Date

No upcoming earnings date has been announced for Editas Medicine, Inc. (EDIT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy EDIT? — Investment Thesis Summary

The quantitative profile for Editas Medicine, Inc. suggests caution. The quality score of 13/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. High volatility (stability score 16/100) increases portfolio risk.

In summary, Editas Medicine, Inc. (EDIT) earns a Reduce rating with a composite score of 26.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on EDIT stock.

Related Resources for EDIT Investors

Explore more research and tools: EDIT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare EDIT head-to-head with peers: EDIT vs AZN, EDIT vs SLGL, EDIT vs VMD.